Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)

Schmid, Sabine; Diem, Stefan; Li, Qiyu; Krapf, Mirjam; Flatz, Lukas; Leschka, Sebastian; Desbiolles, Lotus; Klingbiel, Dirk; Jochum, Wolfram; Früh, Martin

doi:10.1007/s00262-018-2239-4

Cited by 98 publications

(101 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study demonstrated that the tumor response to PD-1 inhibitors in HCC varied among different organs ( Table 2). This diversity of organ-specific response was in line with previous studies and indicates that the immune microenvironments of different organs often differ [4,5,13,20,21]. Further large cohort-based, long-term followup studies are anticipated to determine whether the response patterns to immunotherapies are clinically relevant.…”

Section: Discussionsupporting

confidence: 85%

“…All measurements were conducted by two skilled radiologists using the axial image data according to the RECIST 1.1 and mRECIST. For organ-specific response criteria, modified from RECIST 1.1, a maximum of two measurable target lesions per organ was allowed to evaluate the response to immunotherapies for tumors of individual organ systems [13].…”

Section: Radiological Analysesmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma

et al. 2020

View full text Add to dashboard Cite

Introduction: The tumor microenvironments of different organs often differ and thus may affect the immunotherapy response. Objective: This study elucidated that the efficacy of programmed cell death protein-1 (PD-1) inhibitors varies across different metastatic sites among individuals with advanced hepatocellular carcinoma (HCC). Methods: We retrospectively analyzed treatment outcomes in advanced HCC patients receiving PD-1 inhibitors with or without a combination of tyrosine kinase inhibitors (TKIs). Both the overall response rate (ORR) and organ-specific response rate (OSRR) were assessed using Response Evaluation Criteria in Solid Tumors 1.1 criteria. A survival analysis and its predictors were determined using a multivariate analysis. Results: We analyzed 42 advanced HCC patients (median age: 58.0 years; 78.6% males). Thirty (71.4%) patients were sorafenib-experi-Hsin-Yu Kuo and Nai-Jung Chiang are co-first authors. Hong-Ming Tsai and Yih-Jyh Lin contributed equally to this work.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Radiological Analysesmentioning

confidence: 99%

Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Enhanced immune activity in lymph nodes and lung has been proposed as the cause for better tumor control in these tissues compared to liver, adrenal glands, and bone in a study analyzing organ-specific response patterns in IO-treated NSCLC [32]. Since lymph nodes and lung are also very frequent sites of metastatic involvement in NSCLC, it is not surprising that they showed a higher frequency of OPD in our series ( Table 2).…”

Section: Discussionmentioning

confidence: 57%

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors

Rheinheimer

Heußel

Mayer

et al. 2020

Cancers

View full text Add to dashboard Cite

Oligoprogression (OPD) of non-small-cell lung cancer (NSCLC) occurs in approximately half of patients under targeted compounds (TKI) and facilitates use of regional therapies that can prolong survival. In order to characterize OPD in immunotherapy (IO)-treated NSCLC, we analyzed the failure pattern under PD-1/PD-L1 inhibitors (n = 297) or chemoimmunotherapy (n = 75). Under IO monotherapy, OPD was more frequent (20% vs. 10%, p < 0.05), occurred later (median 11 vs. 5 months, p < 0.01), affected fewer sites (mean 1.1 vs. 1.5, p < 0.05), and involved fewer lesions (1.4 vs. 2.3, p < 0.05) in the first compared to later lines. Lymph nodes (42%, mainly mediastinal) and the brain (39%) were mostly affected, followed by the lung (24%) and other organs. Compared to multifocal progression, OPD occurred later (11 vs. 4 months, p < 0.001) and was associated with longer survival (26 vs. 13 months, p < 0.001) and higher tumor PD-L1 expression (p < 0.001). Chemoimmunotherapy showed a similar incidence of OPD as IO monotherapy (13% vs. 11% at 2 years). Local treatments were applied regularly for brain but only in 50% for extracranial lesions. Thus, NSCLC oligoprogression is less common under IO than under TKI, but also favorable. Since its frequency drops later in the disease, regular restaging and multidisciplinary evaluation are essential in order to exploit the full therapeutic potential.

show abstract

“…Moreover, nine out of 12 patients with BoM had progressive bone lesions at the time of overall tumor progression. 25 Thus, we performed the present study to investigate whether BoM influences the efficacy of ICI treatment in patients with advanced NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Adverse impact of bone metastases on clinical outcomes of patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors

Wang

Chen

et al. 2020

Thoracic Cancer

View full text Add to dashboard Cite

Background: Bone metastasis (BoM) is common in patients with advanced nonsmall cell lung cancer (NSCLC) and considered as one of the negative prognostic factors. However, the impact of BoM on clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors (ICIs) remains unclear. Methods: A total of 103 patients treated with ICI monotherapy and 101 patients treated with ICIs combined with chemotherapy or antiangiogenesis therapy were retrospectively analyzed. The differences in progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) between BoM+ and BoM− were investigated. Results: Of those 101 patients who received combination therapy, no significant difference between BoM− and BoM+ in terms of both median PFS and median OS (median PFS, 10.1 vs. 12.1 months, P = 0.6; median OS, NR vs. 24.6 months, P = 0.713) was determined. In contrast, of the 103 patients who received ICI monotherapy, BoM+ patients had an inferior PFS (4.2 vs. 6.7 months, P = 0.0484) and OS (12.5 vs. 23.9 months, P = 0.0036) compared with BoM− patients. The univariate and multivariate analysis in the ICI monotherapy group also identified BoM as an independent factor attenuating the efficacy of ICI monotherapy. Of all BoM+ patients who received ICI monotherapy, neither palliative radiotherapy nor bisphosphonate drugs improved OS (palliative radiotherapy: 12.5 vs. 16.7 months, P = 0.487; bisphosphonate drugs: 12.5 vs. 9.7 months, P = 0.568). Conclusions: BoM attenuated the efficacy of ICI monotherapy in patients with advanced NSCLC. Of BoM+ patients who received ICI monotherapy, neither palliative radiotherapy nor bisphosphonate drugs improved OS. Other therapeutic strategies are needed for patients with BoM.

show abstract

Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)

Cited by 98 publications

References 27 publications

Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma

Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors

Adverse impact of bone metastases on clinical outcomes of patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors

Contact Info

Product

Resources

About